Nonimmunosuppressive Therapy Bests ARB for Cutting Proteinuira in IgA Nephropathy
AUSTIN, Texas — Once-daily sparsentan (Filspari) was better at reducing proteinuria than standard treatment in IgA nephropathy, according to a prespecified interim analysis of the PROTECT trial. By week 36 of treatment in the phase III study, patients on sparsentan saw a 49.8% reduction from baseline in urine protein-creatinine (UP/C) ratio compared with only a […]
FDA OKs Sparsentan for IgA Nephropathy-Related Proteinuria
The FDA granted accelerated approval to sparsentan (Filspari) for proteinuria in IgA nephropathy, Travere Therapeutics announced, marking the first non-immunosuppressive therapy for this rare condition. Also known as Berger’s disease, proteinuria in IgA nephropathy is the leading cause of kidney failure due to glomerular disease, and sparsentan is specifically indicated to reduce proteinuria in adults […]
Novel Drug Cuts Proteinuria in APOL1-Mediated Kidney Disease
An investigative treatment targeting APOL1 activity significantly improved proteinuria APOL1-mediated kidney disease (AMKD), a proof-of-concept phase IIa study found. In a single-arm, open-label study, treatment with oral VX-147 — a small molecule acting as an APOL1 function inhibitor — significantly reduced urine protein to creatinine ratio (UPCR) by 47.6% (95% CI -60 to -31.3%) by […]